This website is intended only for United States healthcare professionals; if you are not a United States healthcare professional, please visit www.BioMarin.com
This website was developed and funded by BioMarin and is intended for healthcare professionals only. It offers a non-exhaustive selection of materials, including but not limited to publications, presentations, posters and educational materials, to support scientific exchange.
Clinical study results reflect knowledge at the study’s completion and may not be current. Review the methodology, limitations, and authors’ financial disclosures for details.
The information on this website is not medical advice and should not replace independent medical judgment or further research. Content on investigational therapeutics or uses of approved products does not confirm safety or efficacy. BioMarin does not endorse off-label use of its medicines.
As product information may vary by country, please refer to your local health authority regulations and respective approved product information for indications and safety details.

Search

Congress Posters & Presentations

Access PKU related posters and presentations from recent congresses.

Phenylketonuria (PKU)

Filter
Filter by:
Filter by congress:
Filter by year:
Reset all filters
Cancel

Congress Posters and Presentations

Access posters and presentations from recent congresses. All displayed posters and presentations are protected by copyright and are intended for individual use only.
Please Note: Poster content may be unavailable or delayed. This could be due to copyright or embargo guidelines.
You may check back later or contact medinfo@bmrn.com or complete a request form to inquire about this specific material

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR
  • 2026

Validation of the Phenylketonuria-Symptom Severity and Impact Scale (PKU-SSIS) in adults with PKU

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR
  • 2026

Validation of the Phenylketonuria-Symptom Severity and Impact Scale (PKU-SSIS) in adolescents with PKU

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2026

Adolescent immune response determines safety and efficacy of pegvaliase

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2026

Considerations for the use of pegvaliase in adolescents with phenylketonuria

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2026

Development of an algorithm to assess the risk-benefit ratio of the use of pegvaliase during pregnancy

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2026

Achievement of a sustained Phe response in adolescents receiving pegvaliase in an interim analysis of PEGASUS

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2026

Interim analysis of PALLADIUM: A phase 4 study to evaluate a rapid drug desensitization protocol for adults receiving pegvaliase

View content

Poster

View content

New

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2026
  • Burden of Disease

Dietary protein intake variability in individuals with phenylketonuria: Analysis of baseline PRISM data

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GfAS
  • 2026

PALLADIUM: A phase 4 study to evaluate a rapid drug desensitization protocol for adults with phenylketonuria experiencing hypersensitivity reactions to pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GfAS
  • 2026
  • Burden of Disease

Neuropsychiatric comorbidities in adolescents with PKU in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • NPKUA
  • 2026
  • Burden of Disease

Neuropsychiatric comorbidities in adolescents with PKU in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • Rady Children’s Health-UCI
  • 2026
  • Burden of Disease

Neuropsychiatric comorbidities in adolescents with PKU in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR-EU
  • 2025

Real-world healthcare resource utilization in a PKU population: a retrospective observational study in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR-EU
  • 2025

Lifetime secondary healthcare resource utilization in phenylketonuria from birth to adulthood in Sweden

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR-EU
  • 2025

Work complexity in adults with phenylketonuria in Sweden in 2020

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR-EU
  • 2025

Investigating the patient-relevance of achieving blood Phe thresholds in PKU: Results from an analysis of the OPAL study

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ISPOR-EU

Estimating healthcare resource use associated with the treatment of phenylketonuria in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ESPKU
  • 2025
  • Safety Profile and Efficacy

Index of sustained Phe response and improvements in PKU clinical outcome assessments in patients receiving pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ESPKU
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Improvements in blood phenylalanine and health-related quality of life outcomes among adults with PKU receiving pegvaliase in the OPAL study

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Safety Profile and Efficacy

Safety and efficacy of pegvaliase in adolescents with phenylketonuria: Primary results from PEGASUS, a phase 3 open-label randomized controlled study

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Safety Profile and Efficacy

PALLADIUM: A phase 4 study to evaluate a rapid drug desensitization protocol for adults with phenylketonuria experiencing hypersensitivity reactions to pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Real-world safety and tolerability of pegvaliase: A non-interventional surveillance study in Japan

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Burden of Disease

Neuropsychiatric comorbidities in adolescents with PKU in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Burden of Disease

Work ability in adults with PKU in Sweden in 2020

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Burden of Disease

Lifetime monitoring of Phe levels in PKU from birth to adulthood in the Swedish Registry for Inherited Metabolic Diseases

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ICIEM
  • 2025
  • Burden of Disease

Neuropsychiatric comorbidities in adults with PKU in Sweden

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SERGG
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Improvements in blood phenylalanine and health-related quality of life outcomes among adults with PKU receiving pegvaliase in the OPAL study

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SERGG
  • 2025
  • Safety Profile and Efficacy

Index of sustained Phe response and improvements in PKU clinical outcome assessments in patients receiving pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GARROD
  • 2025
  • Safety Profile and Efficacy

Index of sustained Phe response and improvements in PKU clinical outcome assessments in patients receiving pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GARROD
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Improvements in blood phenylalanine and health-related quality of life outcomes among adults with PKU receiving pegvaliase in the OPAL study

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Occurrence of anaphylaxis in adult incident pegvaliase-treated PKU patients in a post-marketing safety analysis in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2025
  • Safety Profile and Efficacy

Index of sustained Phe response and improvements in PKU clinical outcome assessments in patients receiving pegvaliase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Initial psychometric evaluation of the Adult Symptom Severity and Impacts Scale (PKU-SSIS) using an interim data cut from the OPAL study

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2025

The Assessment of the Treatment and Management Landscape of Phenylketonuria Survey Study: Findings from 19 Clinics in the United States

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2025
  • Real World Evidence
  • Safety Profile and Efficacy

Improvements in blood phenylalanine and health-related quality of life outcomes among adults with PKU receiving pegvaliase in the OPAL study

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2024
  • Safety Profile and Efficacy

Final safety and efficacy of pegvaliase in Japanese adults with phenylketonuria

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2024
  • Burden of Disease

Assessment of the Treatment and Management LAndScape of Phenylketonuria: ATLAS Survey Study in Japan

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • NPKUA
  • 2024

Exploring the landscape of phenylketonuria education and learning needs of genetics trainees

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • NPKUA
  • 2024
  • Real World Evidence
  • Safety Profile and Efficacy

Lessons learned from 5 years of experience with pegvaliase in US clinics: a case series

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2024
  • Real World Evidence
  • Safety Profile and Efficacy

Lessons learned from 5 years of experience with pegvaliase in US clinics: a case series

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2024
  • Real World Evidence
  • Safety Profile and Efficacy

Reduction of blood phenylalanine in participants enrolled in OPAL, an observational study, mirror findings from the US-based PRISM population

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2024

Exploring the landscape of phenylketonuria education and learning needs of genetic trainees

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2023
  • Safety Profile and Efficacy

Three-year interim safety and efficacy of pegvaliase in Japanese adults with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2023
  • Burden of Disease

Evaluating trends in metabolic control and treatment history among pegvaliase trial participants

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2023
  • Burden of Disease

Systematic literature review of prevalence and severity of somatic comorbidities in adults with PKU

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2023
  • Burden of Disease

Evaluating trends in self-rated historic metabolic control and treatment history among PRISM participants

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2023
  • Real World Evidence

OPAL: A multicenter, observational study to evaluate the real-world outcomes of pegvaliase in adults with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2023

Design of a global, multicenter study to assess maternal, fetal, and infant outcomes of pegvaliase exposure during pregnancy and breastfeeding

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SERGG
  • 2023

Design of a global, multicenter study to assess maternal, fetal, and infant outcomes of pegvaliase exposure during pregnancy and breastfeeding

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SERGG
  • 2023
  • Safety Profile and Efficacy

The long-term safety and efficacy of pegvaliase 60 mg/day in adults with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2023

Design of a global, multicenter study to assess maternal, fetal, and infant outcomes of pegvaliase exposure during pregnancy and breastfeeding

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2023
  • Burden of Disease

Evaluating trends in self-rated historic metabolic control and treatment history among PRISM participants

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2022
  • Safety Profile and Efficacy

Two-year Interim Safety and Efficacy of pegvaliase in Japanese adults with Phenylketonuria

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2022
  • Safety Profile and Efficacy

The long-term safety and efficacy of pegvaliase 60 mg/day in adults with Phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022
  • Real World Evidence
  • Safety Profile and Efficacy

Kuvan® Adult Maternal Paediatric European Registry (KAMPER): Final results in phenylketonuria (PKU) patients

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022
  • Real World Evidence
  • Safety Profile and Efficacy

Efficacy and safety of sapropterin before and during pregnancy: Final analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER) and Phenylketonuria Developmental Outcomes and Safety (PKUDOS) PKU-MOMs sub-registries

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022
  • Safety Profile and Efficacy

Efficacy and safety of the recommended pegvaliase dosing regimen in adults with phenylketonuria in the phase 3 PRISM studies

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022

Design of a phase 3 open-label randomized controlled multi-center study evaluating the safety and efficacy of pegvaliase in adolescents (ages 12–17) with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022
  • Burden of Disease

Assessing the health status of ≥16-year-old patients with early-diagnosed PKU from the retrospective analysis of the full French insurance claims cohort 2006-2018

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SSIEM
  • 2022
  • Burden of Disease

Assessing the health status of patients with late-diagnosed PKU from the retrospective analysis of the full French insurance claims cohort 2006-2018

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • NPKUA
  • 2022

Design of a phase 3 open-label randomized controlled multi-center study evaluating the safety and efficacy of pegvaliase in adolescents (ages 12–17) with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2022
  • Safety Profile and Efficacy

Efficacy and safety of the recommended pegvaliase dosing regimen in adults with phenylketonuria in the phase 3 PRISM studies

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • SIMD
  • 2022
  • Safety Profile and Efficacy

Efficacy and safety of the recommended pegvaliase dosing regimen in adults with phenylketonuria in the phase 3 PRISM studies

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2021

Phenom: A prospective clinical study on the clinical impact of phenylketonuria in adults (307-902)

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2021
  • Burden of Disease

Measuring phenylketonuria burden of illness: Development of the Phenylketonuria Symptom Severity and Impacts Scale as a robust patient reported outcome

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2021
  • Burden of Disease

Birth prevalence of phenylalanine hydroxylase deficiency: A systematic literature review and meta-analysis

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2021
  • Safety Profile and Efficacy

ENDURE: A phase IV, open-label trial to assess the responsiveness of patients with phenylketonuria in Denmark to treatment with sapropterin over 28 days

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2021
  • Burden of Disease

Measuring phenylketonuria burden of illness: Development of the Phenylketonuria Symptom Severity and Impacts Scale as a robust patient reported outcome

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2021
  • Safety Profile and Efficacy

Study 165-305: Interim Safety and Efficacy of Pegvaliase in Japanese Adults with Phenylketonuria

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • JSIMD
  • 2021
  • Safety Profile and Efficacy

Efficacy and Safety of the recommended Pegvaliase dosing regimen in adults with Phenylketonuria in the Phase 3 Prism Studies

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Efficacy and safety of pegvaliase in patients aged 16 and 17 years with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Update of efficacy and safety of pegvaliase for the treatment of adults with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Efficacy and safety of pegvaliase 60 mg dose in adult patients with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: Results from phase 2 and 3 clinical trials

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020

A prospective clinical study on the clinical impact of phenylketonuria in adolecents and adults: Phenom study design

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Effect of sapropterin dihydrochloride on IQ preservation in children (aged 0–6 years) with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ASHG
  • 2020

High Phenylalanine Concentration Contributes to the Stability of the F263S-variant of Phenylalanine Hydroxylase

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2020
  • Safety Profile and Efficacy

Dietary intakes and adverse events in pegvaliase-treated phenylketonuria adults who had low blood phenylalanine concentrations

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GARROD
  • 2023
  • Burden of Disease

Systematic literature review of the prevalence and severity of somatic comorbidities in adults with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GARROD
  • 2023
  • Burden of Disease

Evaluating trends in self-rated historic metabolic control and treatment history among PRISM participants

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ACMG
  • 2023
  • Burden of Disease

Systematic literature review of the prevalence and severity of somatic comorbidities in adults with phenylketonuria

View content

Presentation

View content

  • Congresses
  • Phenylketonuria (PKU)
  • ASHG
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Efficacy & safety of pegvaliase 60mg in adult patients with PKU

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2020
  • Safety Profile and Efficacy

Effect Of Sapropterin Dihydrochloride On IQ Preservation In Children (Aged 0-6 Years) With Phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Efficacy and safety of pegvaliase 60 mg dose in adult patients with phenylketonuria

View content

Poster

View content

  • Congresses
  • Phenylketonuria (PKU)
  • GMDI
  • 2020
  • Safety Profile and Efficacy

Phase 3 PRISM studies: Efficacy and safety of pegvaliase in patients 16-17 years of age with phenylketonuria

View content